Skip to Content
Merck

Skip To

A8598

Ancitabine hydrochloride

Synonym(s):

2,2′-Anhydro-(1-β-D-arabinofuranosyl)cytosine hydrochloride, Cyclo-C, Cyclocytidine

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C9H11N3O4 · HCl
CAS Number:
Molecular Weight:
261.66
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
233-515-6
MDL number:
Form:
powder
Quality level:
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


form

powder

Quality Level

SMILES string

Cl[H].OC[C@H]1[C@H](O)O[C@@H]2[C@H]1OC3=NC(=N)C=C[N@@H]23

InChI

1S/C9H11N3O4.ClH/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8;/h1-2,4,6-8,10,13-14H,3H2;1H/t4-,6-,7+,8-;/m1./s1

InChI key

KZOWNALBTMILAP-JBMRGDGGSA-N

Application

Ancitabine hydrochloride is an antineoplastic agent for the treatment of lymphatic leukemia and sinus acceleration.

Biochem/physiol Actions

Antineoplastic

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
C1768C6645251010
form

powder

form

crystalline

form

crystalline

form

solid

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

100


Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

Muta. 2



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Tyramine-like effect of cyclocytidine (2,2'-anhydro-1-β-arabinofuranosylcytosine hydrochloride), an antineoplastic agent
Oguro, K., Hashimoto, K.
The Journal of Experimental Medicine, 124, 83-90 (1978)
M Hewish et al.
British journal of cancer, 108(4), 983-992 (2013-01-31)
DNA mismatch repair deficiency is present in a significant proportion of a number of solid tumours and is associated with distinct clinical behaviour. To identify the therapeutic agents that might show selectivity for mismatch repair-deficient tumour cells, we screened a



Global Trade Item Number

SKUGTIN
A8598-1G04061826740965

Questions

Reviews

No rating value

Active Filters